Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.

Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O’Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfeld C, Bekaii-Saab T, O’Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Dri-lon A; eNRGy Investigators. N Engl J Med. 2025 Feb 6;392(6):566-576. doi: 10.1056/NEJMoa2405008. PMID: 39908431 Clinical Trial.

Electrotherapy as treatment for chemotherapy-induced peripheral neuropathy – a randomized controlled trial.

Sassmann R, Gampenrieder SP, Rieder F, Johansson T, Rinnerthaler G, Castag-naviz V, Lampl K, Herfert J, Kienberger YT, Flamm M, Schaffler-Schaden D, Greil R. Front Neurol. 2024 Dec 24;15:1451456. doi: 10.3389/fneur.2024.1451456. eCollection 2024. PMID: 39777312.

Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.

Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Brag-hiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; Check-Mate 8HW Investigators. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141.PMID: 39602630 Clinical Trial.

Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A com-parative analysis in a European real-world cohort.

de Castro T, Welland S, Jochheim L, Leyh C, Shmanko K, Finkelmeier F, Jeliaz-kova P, Jefremow A, Gonzalez-Carmona MA, Kandulski A, Roessler D, Ben Kha-led N, Enssle S, Venerito M, Fründt TW, Schultheiß M, Djanani A, Pangerl M, Maieron A, Wirth TC, Marquardt JU, Greil R, Fricke C, Günther R, Schmiderer A, Bettinger D, Wege H, Scheiner B, Müller M, Strassburg CP, Siebler J, Ehmer U, Waidmann O, Weinmann A, Pinter M, Lange CM, Saborowski A, Vogel A. Hepatol Commun. 2024 Nov 4;8(11):e0562. doi: 10.1097/HC9.0000000000000562. eCollection 2024 Nov 1. PMID: 39495153.

Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis.

Luciano M, Sieberer H, Krenn PW, Dang HH, Vetter J, Neuper T, Amend D, Blöchl C, Weichenberger CX, Eglseer A, Unger MS, Andosch A, Steiner P, Neureiter D, Bauer R, Hummer L, Tesanovic S, Binder S, Elmer DP, Strandt H, Schaller S, Strunk D, Pleyer L, Greil R, Winkler S, Hartmann TN, Schmidt-Arras D, Huber CG, Aberger F, Horejs-Hoeck J. Cell Commun Signal. 2024 Sep 2;22(1):424. doi: 10.1186/s12964-024-01777-6. PMID: 39223663.

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neo-adjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Blasi O, Callari M, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Clin Cancer Res. 2024 Sep 23:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0149. Online ahead of print. PMID: 39308141.

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.

Matikas A, Möbus V, Greil R, Andersson A, Steger GG, Untch M, Fornander T, Malmström P, Schmatloch S, Johansson H, Hellström M, Brandberg Y, Gnant M, Loibl S, Foukakis T, Bergh J; SweBCG, ABCSG and GBG. J Clin Oncol. 2024 Sep 10;42(26):3077-3082. doi: 10.1200/JCO.24.00178. Epub 2024 Jul 17. PMID: 39018515.

Comorbidity and adverse events in acquired hemophilia A: data from the GTH-AHA-EMI study.

Burgmann CH, Sachs UJ, Trautmann-Grill K, Pfrepper C, Knöbl P, Greil R, Olden-burg J, Miesbach W, Holstein K, Eichler H, Möhnle P, Höpting M, Dobbelstein C, Klamroth R, Tiede A. Res Pract Thromb Haemost. 2024 Sep 5;8(7):102565. doi: 10.1016/j.rpth.2024.102565. eCollection 2024 Oct. PMID: 39420971.

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zim-mermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Re-search; Arbeitsgemeinschaft Medikamentöse Tumortherapie; Nordic Lymphoma Group; Australasian Leukaemia and Lymphoma Group. Lancet. 2024 Jul 3:S0140-6736(24)01315-1. doi: 10.1016/S0140-6736(24)01315-1. Online ahead of print. PMID: 38971175.

QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.

Ludwig H, Melchardt T, Schweitzer I, Sormann S, Schreder M, Andel J, Hartmann B, Zojer N, Schöffmann L, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bozic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Knop S, Greil R. EJHaem. 2024 May 17;5(3):494-504. doi: 10.1002/jha2.925. eCollection 2024 Jun. PMID: 38895059.